<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990236</url>
  </required_header>
  <id_info>
    <org_study_id>001-01</org_study_id>
    <nct_id>NCT00990236</nct_id>
  </id_info>
  <brief_title>Thrombelastography Based Dosing of Enoxaparin</brief_title>
  <official_title>Thrombelastography Based Dosing of Enoxaparin for Thromboprophylaxis: a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Foundation, Oregon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Trauma Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many
      times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing
      clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not
      fully prevent the development of these clots especially in critically ill or obese patients.
      Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography
      (TEG®) can be used to measure how blood clots. The purposes of this study are:

        -  to learn if the TEG® can better guide physicians in prescribing an effective dose of
           Lovenox compared to standard doses recommended by the drug company in preventing blood
           clots from developing in the legs and lungs, and

        -  to compare the development of blood clots in patients receiving the standard dose of
           enoxaparin compared to patients receiving a TEG® guided dose of enoxaparin.

        -  to determine if TEG guided dosing results in decreased bleeding complications compared
           to standard dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:

      Enoxaparin dosed to maintain a TEG® ΔR greater than 1.0 minute will decrease the incidence of
      DVT compared to standard dosing.

      Initiation of enoxaparin thromboprophylaxis will be done by the treatment team. Once
      enrolled, the subject will be randomized to continue receiving standard dose enoxaparin (30
      mg twice daily) or variable TEG® guided enoxaparin dosing. The treatment team and the subject
      will be blinded regarding the arm in which the patient is enrolled. Patient characteristics:
      age, gender, body mass index (BMI), comorbidities, Acute Physiology and Chronic Health
      Evaluation II score (APACHE II), injuries, and operations will be collected. As part of
      standard protocol in the ICU, all patients will undergo weekly ultrasound duplex examination
      of the lower extremities for presence of deep venous thrombosis.

      A baseline TEG® will be completed on each patient when they are enrolled in the study. The
      blood will be drawn between four and six hours after the morning dose is administered,
      corresponding to maximum tissue levels of enoxaparin. TEG® assays will be run in duplicate
      for each patient, with and without heparinase, which negates the effects of enoxaparin in the
      assay.

      Those patients randomized to the control arm of the study will have TEG® performed at
      baseline and daily for one week, then twice weekly. The twice weekly TEG® assays will be done
      until the patient is discharged from inpatient care or enoxaparin is discontinued by the
      treatment team. No adjustments will be made to their enoxaparin dosing.

      Patients in the TEG® guided enoxaparin dosing arm will start treatment as ordered by the
      primary treatment team. After the second TEG®, the dose of enoxaparin will be adjusted in 10
      mg increments per dose in order to reach a target ΔR between 1.0 and 1.4 minutes. If the
      initial ΔR is greater than 1.4 minutes, the dose of enoxaparin will be decreased by 10 mg
      increments until the target ΔR is achieved. Patients will have TEGs® performed daily and
      adjustment of dosing until the target ΔR is reached. Once the target ΔR is achieved, TEG®
      will be done twice weekly until the patient is discharged from inpatient care or enoxaparin
      is discontinued by the treatment team. All patients will be assessed daily by study personnel
      for bleeding complications. If bleeding complications occur, subjects will be withdrawn from
      the study. If interim analysis identifies a significant difference in bleeding complications
      between groups the study will be terminated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Deep Vein Thrombosis (DVT)</measure>
    <time_frame>Through study completion, assessed up to 120 days post randomization</time_frame>
    <description>An ultrasound duplex will be completed at least one time after randomization to determine if the subject has developed a DVT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bleeding Complications</measure>
    <time_frame>Through study completion, assessed up to 120 days post randomization</time_frame>
    <description>An increase in bleeding complications will be assessed daily during hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Thromboembolic Complications</condition>
  <arm_group>
    <arm_group_label>Enoxaparin 30 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard dose enoxaparin thromboprophylaxis (30 mg twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin dose adjusted based on TEG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoxaparin dose modified based on TEG results</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin dose adjusted Lovenox based on TEG</intervention_name>
    <description>Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
    <arm_group_label>Enoxaparin dose adjusted based on TEG</arm_group_label>
    <other_name>enoxaparin, lovenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 30 mg BID</intervention_name>
    <description>Enoxaparin dose of 30 mg twice a day without any adjustments</description>
    <arm_group_label>Enoxaparin 30 mg BID</arm_group_label>
    <other_name>enoxaparin, lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient initiated on enoxaparin thromboprophylaxis

          -  Age greater than 15 years

        Exclusion Criteria:

          -  Unable to obtain consent from patient or ARR

          -  Presence of: intracranial hemorrhage, brain injury

          -  Receiving therapeutic dose enoxaparin

          -  Receiving other forms of anticoagulation

          -  Receiving non-standard dosing regimen of enoxaparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schreiber, MD FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <results_first_submitted>March 2, 2020</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Martin A Schreiber, MD</investigator_full_name>
    <investigator_title>Professor &amp; Chief of Trauma</investigator_title>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>superficial venous thrombosis</keyword>
  <keyword>pulmonary embolus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exoxaparin 30 mg BID</title>
          <description>standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
        </group>
        <group group_id="P2">
          <title>Enoxaparin Dose Adjusted Based on TEG</title>
          <description>enoxaparin dose modified based on TEG results
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exoxaparin 30 mg BID</title>
          <description>standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
        </group>
        <group group_id="B2">
          <title>Enoxaparin Dose Adjusted Based on TEG</title>
          <description>enoxaparin dose modified based on TEG results
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="89"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" lower_limit="28.0" upper_limit="60.0"/>
                    <measurement group_id="B2" value="48.5" lower_limit="33.8" upper_limit="58.2"/>
                    <measurement group_id="B3" value="46.0" lower_limit="32.0" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="89"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="89"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of Deep Vein Thrombosis (DVT)</title>
        <description>An ultrasound duplex will be completed at least one time after randomization to determine if the subject has developed a DVT.</description>
        <time_frame>Through study completion, assessed up to 120 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exoxaparin 30 mg BID</title>
            <description>standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin Dose Adjusted Based on TEG</title>
            <description>enoxaparin dose modified based on TEG results
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Deep Vein Thrombosis (DVT)</title>
          <description>An ultrasound duplex will be completed at least one time after randomization to determine if the subject has developed a DVT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Bleeding Complications</title>
        <description>An increase in bleeding complications will be assessed daily during hospitalization</description>
        <time_frame>Through study completion, assessed up to 120 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exoxaparin 30 mg BID</title>
            <description>standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin Dose Adjusted Based on TEG</title>
            <description>enoxaparin dose modified based on TEG results
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Bleeding Complications</title>
          <description>An increase in bleeding complications will be assessed daily during hospitalization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for a period up to 120 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exoxaparin 30 mg BID</title>
          <description>standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
        </group>
        <group group_id="E2">
          <title>Enoxaparin Dose Adjusted Based on TEG</title>
          <description>enoxaparin dose modified based on TEG results
Dose-adjusted Lovenox based on TEG: Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R &lt; 1.0 min - increase dose by 10 mg BID; delta-R &gt;/= 1.0 min and &lt;/= 2.0 min - no change; delta-R &gt; 2.0 min - decrease dose by 10 mg BID.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samantha Underwood, Research Manager</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-8481</phone>
      <email>traumare@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

